文 献 8）Bahadur MM, Dhope N, Kaimal RR, Shingare A. Pilot study of valganciclovir-induced leukopenia in kidney transplant recipients with NUDT15 genetic variation. Kidney Int Rep 2024; 9(10): 3070-3. 9）Yamaguchi M, Iwata KI, Fukuda Y Haruta K, Suzuki T, Torii Y, et al. Association Between NUDT15 R139C genotype and neutropenia during antiviral therapy in patients with congenital cytomegalovirus infection. Pediatr Infect Dis J 2023; 42(7): e256-7.10）“Gene-Specific Information Tables for NUDT15,” PharmGKB [https://www.pharmgkb.org/page/ nudt15RefMaterials (accessed 2025-2-14)]11）Asada A, Nishida A, Shioya M, Imaeda H, Inatomi O, Bamba S, et al. NUDT15 R139C-related thiopurine leukocytopenia is mediated by 6-thioguanine nucleotide-independent mechanism in Japanese patients with inflammatory bowel disease. J Gastroenterol 2016; 51(1): 22-9.12）Kakuta Y, Kawai Y, Okamoto D Takagawa T, Ikeya K, Sakuraba H, et al. NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study. J Gastroenterol 2018; 53(9): 1065-78.13）Iwata KI, Torii Y, Fukuda Y, Haruta K, Yamaguchi M, Suzuki T, et al. Associations of nucleoside diphosphate-linked moiety X-type motif 15 variants with neutropenia during antiviral therapy for cytomegalovirus disease in pediatric liver transplant recipients. Transpl Infect Dis 2025; e70079.172 1）Howley PM, Knipe DM, Whelan SPJ, Freed EO, Cohen JL (Eds). Fields virolog. 7th ed, Lippincott Williams & Wilkins, 2022. 2）Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33(9): e13512. 3）Silva Junior HT, Tokat Y, Cai J, Singh I, Sandhu A, Demuth D, et al. Epidemiology, management, and burden of cytomegalovirus in solid organ transplant recipients in selected countries outside of Europe and North America: A systematic review. Transpl Infect Dis 2023; 25(4): e14070. 4）Kimberlin DW, Jester PM, Sánchez PJ, Ahmed A, Arav-Boger R, Michaels MG, et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med 2015; 372(10): 933-43. 5）Relling MV, Schwab M, Whirl-Carrillo M, Suarez-Kurtz G, Pui CH, Stein CM, et al. Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update. Clin Pharmacol Ther 2019; 105(5): 1095-105. 6）Moriyama T, Nishii R, Perez-Andreu V, Yang W, Klussmann FA, Zhao X, et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet 2016; 48(4): 367-73. 7）Nishii R, Mizuno T, Rehling D, Smith C, Clark BL, Zhao X, et al. NUDT15 polymorphism influences the metabolism and therapeutic effects of acyclovir and ganciclovir. Nat Commun 2021; 12(1): 4181.
元のページ ../index.html#188